Emerging · Research guide

Urolithin A for dogs: could better mitochondrial maintenance protect muscle?

The mitophagy mechanism and human endurance findings are interesting. Direct evidence for an oral muscle benefit in dogs is still missing.

The takeaway

Nara’s take.

Urolithin A is one of the more coherent mitochondrial-ageing ideas to follow. The strongest reason for interest comes from mechanistic work and human trials, not demonstrated improvements in the strength or healthspan of supplemented pet dogs.

How it may work

What mitophagy means in plain language

Mitophagy is a process that helps cells remove damaged mitochondria. Urolithin A has been studied as a way to influence that maintenance process, rather than simply supplying an antioxidant or extra fuel.

Foundational experiments reported mitophagy-related effects, longer lifespan in worms and improved muscle function in rodents. Those are different results in different species; they should not be compressed into 'urolithin A makes mammals live longer' or a claim about dogs.

Sources: [1]

What the research shows

The human trial is promising, but not uniformly positive

A randomized trial in older adults reported improvements in secondary muscle-endurance measures at two months and some mitochondrial-related biomarkers. The between-group endurance differences were not statistically significant at four months. Its primary comparisons for six-minute walking distance and maximal ATP production were also not statistically significant.

That combination matters. There is a functional signal worth investigating, but not a consistent win across outcomes and time points. The study was funded by Amazentis, which participated in its conduct and reporting; several authors disclosed commercial relationships. It is evidence in older people, not a validated canine dose or a guarantee for an active, healthy dog.

Sources: [2]

What the research shows

Canine cells are not the same as a treated dog

A 2026 experiment tested urolithin A in stored canine sperm and reported favourable motility, antioxidant and mitochondrial findings. This is direct work with canine-derived material, but it is an ex vivo storage experiment.

Adding a compound to a storage medium does not establish what happens after a dog swallows it. Absorption, tissue exposure, metabolism, the target organ and long-term tolerability are all separate questions. The study should not be presented as evidence that an oral product preserves muscle in living dogs.

Sources: [3]

Nara's practical guidance

What this means for your dog

Nara considers the mechanism credible enough to follow closely, while keeping the owner decision honest: a demonstrated canine muscle benefit and a well-defined long-term regimen are not established. A supplement cannot be assumed to replace appropriate movement or adequate nutrition just because it targets a related pathway.

Before spending on an ongoing product, distinguish an experimental personal choice from a treatment for weakness or wasting. Those signs deserve assessment. The evidence that would change Nara's position is a controlled oral canine study showing a meaningful functional gain alongside credible exposure and safety data—not another isolated mitochondrial marker.

Evidence informing this guidance: [2], [1], [4]

Follow the evidence

Sources and review notes.

Primary studies, clinical guidance and explicitly labelled sponsor disclosures. A mechanism, an observational association and a treatment result are different kinds of evidence.

Editorial research update: 2026-09-24. These guides build on Nara’s existing source records and a fresh check of accessible primary abstracts, full texts and official pages. This is not an exhaustive systematic review or a new independent clinical review. The evidence assessment retains its own date and status. Practical examples are Nara’s interpretation, not validated treatment protocols.

[1] 2016 · C. elegans and rodents · Preclinical mechanistic and intervention study
Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents
Ryu D et al.. Nature Medicine.
10.1038/nm.4132
Foundational mitophagy, worm-lifespan and rodent muscle-function evidence underlying translational interest.
[2] 2022 · Human · Randomized double-blind placebo-controlled trial
Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial
Liu S et al.. JAMA Network Open.
10.1001/jamanetworkopen.2021.44279
Human translational trial with improved secondary endurance and biomarker measures but nonsignificant primary 6-minute-walk and ATP-production comparisons.
[3] 2026 · Dog · Ex vivo controlled canine semen experiment
Urolithin A improves motility, antioxidant defense, and mitochondrial function of chilled canine spermatozoa during 72-h liquid storage
Mirzaei R; Soleimanzadeh A; Asri-Rezaei S. Scientific Reports.
10.1038/s41598-026-49089-8
Direct canine-derived mitochondrial and sperm-function evidence, but not an oral or in vivo efficacy study.
[4] 2023 · Dog and cat; this guide uses the dog-specific guidance · Veterinary clinical guideline, not an intervention trial
2023 AAHA Senior Care Guidelines for Dogs and Cats: Nutrition
American Animal Hospital Association. AAHA.
Official guideline, nutrition section
Nutritional assessment, muscle loss, appropriate energy and protein in older dogs.

Keep reading

Connected questions.

Muscle preservation

Defending lean mass through mid and late life, rather than reacting to visible loss.

Creatine

Cellular energy buffering and muscle performance, largely untested in dogs.

Astaxanthin

A carotenoid antioxidant with limited canine outcome data.

Open Nara’s evidence assessment

The guide above explains the topic. This separate record preserves the accepted claim, confidence, limitations and safety context. Publishing an article does not upgrade the science or turn an experimental intervention into a recommendation.

Nara’s evidence view

Research watchlist

PreliminaryCanine safety or pharmacokineticsLow confidence

The claim we’re evaluating

Oral urolithin A meaningfully improves mitochondrial or muscle-related healthy-aging outcomes in dogs.

Nara’s interpretation

Urolithin A is one of the more scientifically credible emerging mitochondrial interventions, but the evidence for meaningful benefit in dogs is not yet direct. Human trials provide preliminary evidence for some muscle-performance and mitochondrial-related effects, while preclinical work strongly supports mitophagy as a mechanism; neither establishes canine healthspan benefit. Nara would therefore treat urolithin A as a research-watchlist intervention rather than as a demonstrated canine healthy-aging intervention.

How we reached this view

What the evidence shows

Direct living-dog evidence identified through the cutoff is primarily pharmacokinetic and acute-safety evidence rather than efficacy evidence. A 2026 canine study found improved motility, antioxidant measures and mitochondrial-energy measures when urolithin A was added directly to chilled canine semen, but this was an ex vivo reproductive-biotechnology experiment and does not demonstrate systemic benefit from oral supplementation. Human randomized trials provide stronger translational evidence: urolithin A has altered mitochondrial-related molecular and metabolic markers and improved some muscle-endurance or performance measures, but an important older-adult trial did not significantly improve its primary 6-minute-walk or maximal ATP-production endpoints versus placebo. Preclinical evidence includes mitophagy induction, lifespan extension in C. elegans and muscle-function effects in rodents.

Important limitations

No verified randomized canine trial was identified showing that oral urolithin A improves mobility, muscle strength, exercise capacity, cognition, disease incidence, healthspan or lifespan.
The 2026 canine sperm study exposed sperm directly to urolithin A ex vivo; it cannot be treated as evidence for oral supplementation in a living dog.
Mitophagy is well supported mechanistically in non-canine models, but demonstrating mitophagy does not itself demonstrate a meaningful health outcome.
Human efficacy is not uniformly positive: the older-adult randomized trial missed its prespecified primary functional and ATP-production comparisons while showing benefits on secondary endurance and biomarker endpoints.
Available canine oral pharmacokinetic/safety evidence is small and does not establish chronic safety or efficacy.

What would change Nara’s view

What would strengthen our view

A randomized, blinded canine trial demonstrating a reproducible improvement in a prespecified functional endpoint such as strength, endurance, mobility or recovery rather than only molecular biomarkers.
Replication in independently conducted canine studies using orally administered urolithin A and clinically relevant populations.
Canine evidence linking mitochondrial changes to meaningful functional outcomes over a sufficiently long follow-up period.

What could weaken our view

Well-powered canine trials showing no functional advantage despite verified systemic exposure.
Replication of human null findings across prespecified functional endpoints despite biomarker changes.
Evidence of clinically important adverse effects or unfavorable chronic safety findings in dogs.

What could change our position

Replicated canine functional-outcome evidence with acceptable safety could justify movement toward reasonable_to_consider.
Consistent null canine efficacy trials would favor not_currently_supported for a canine healthy-aging claim.
A reproducible meaningful canine safety signal could justify potential_concern.

Safety and clinical context

Existing canine pharmacokinetic/acute-safety evidence should not be interpreted as proof of chronic safety.
Formulation-dependent pharmacokinetics further limit extrapolation between experimental products.
The ex vivo concentrations used in canine semen research provide no owner-directed oral dosing information.

Evidence record

Nara position: Research watchlist
Evidence maturity: Preliminary
Most direct relevant evidence: Canine safety or pharmacokinetics
Overall confidence: Low confidence
Evidence reviewed through: 2026-08-12
Assessment date: 2026-08-12
Review status: Initial Nara internal evidence assessment
Framework: Nara Evidence Framework v1.0

How Nara evaluates science

Anchor sources

Urolithin A improves motility, antioxidant defense, and mitochondrial function of chilled canine spermatozoa during 72-h liquid storage

Scientific Reports · 2026 · Dog

Ex vivo controlled canine semen experiment

Direct canine-derived mitochondrial and sperm-function evidence, but not an oral or in vivo efficacy study.

10.1038/s41598-026-49089-8

Nanoparticles that do not compete with endogenous ligands – Molecular characterization in vitro, acute safety in canine, and interspecies pharmacokinetics modeling to humans

Journal of Controlled Release · 2021 · Dog and translational models

Canine acute safety/pharmacokinetic study

Provides direct canine systemic-exposure and acute-safety information for urolithin A formulations; not efficacy evidence.

10.1016/j.jconrel.2021.02.009

Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial

JAMA Network Open · 2022 · Human

Randomized double-blind placebo-controlled trial

Human translational trial with improved secondary endurance and biomarker measures but nonsignificant primary 6-minute-walk and ATP-production comparisons.

10.1001/jamanetworkopen.2021.44279

Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents

Nature Medicine · 2016 · C. elegans and rodents

Preclinical mechanistic and intervention study

Foundational mitophagy, worm-lifespan and rodent muscle-function evidence underlying translational interest.

10.1038/nm.4132

Your dog’s context

Bring this back to your dog.

Loading your dog’s context…